These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22160207)

  • 1. Antiretroviral drug treatment of CNS HIV-1 infection.
    Yilmaz A; Price RW; Gisslén M
    J Antimicrob Chemother; 2012 Feb; 67(2):299-311. PubMed ID: 22160207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy.
    Tamarit Mdel P; Quereda C; Gonzalez-Rozas M; Corral I; Casado JL
    AIDS Res Hum Retroviruses; 2012 Jan; 28(1):83-6. PubMed ID: 21504362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV/AIDS pathogenesis and treatment options focusing on the viral entry inhibitors.
    Jones R; Gazzard B
    Expert Rev Anti Infect Ther; 2006 Apr; 4(2):303-12. PubMed ID: 16597210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Determination of serum levels of antiretroviral drugs].
    Kurowski M
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():62-4. PubMed ID: 15373053
    [No Abstract]   [Full Text] [Related]  

  • 6. Mechanism of HIV antiretroviral drugs progress toward drug resistance.
    Ammaranond P; Sanguansittianan S
    Fundam Clin Pharmacol; 2012 Feb; 26(1):146-61. PubMed ID: 22118474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis.
    Limoges J; Poluektova L; Ratanasuwan W; Rasmussen J; Zelivyanskaya M; McClernon DR; Lanier ER; Gendelman HE; Persidsky Y
    Virology; 2001 Mar; 281(1):21-34. PubMed ID: 11222092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical implications of genotypic resistance to the newer antiretroviral drugs in HIV-1-infected patients with virological failure.
    Llibre JM; Schapiro JM; Clotet B
    Clin Infect Dis; 2010 Mar; 50(6):872-81. PubMed ID: 20158400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.
    Gerber JG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S123-9. PubMed ID: 10860896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.
    Taiwo B; Hicks C; Eron J
    J Antimicrob Chemother; 2010 Jun; 65(6):1100-7. PubMed ID: 20348088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 infection and cognitive impairment in the cART era: a review.
    Schouten J; Cinque P; Gisslen M; Reiss P; Portegies P
    AIDS; 2011 Mar; 25(5):561-75. PubMed ID: 21160410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection.
    Bruno CJ; Jacobson JM
    J Antimicrob Chemother; 2010 Sep; 65(9):1839-41. PubMed ID: 20639524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infants with CMV and HIV-1.
    Rohrer TR; Engelcke G; Rudin C
    N Engl J Med; 1999 Nov; 341(19):1476-7. PubMed ID: 10577105
    [No Abstract]   [Full Text] [Related]  

  • 14. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
    Grant PM; Zolopa AR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical impact of combination antiretroviral therapy].
    Gatanaga H
    Nihon Rinsho; 2002 Apr; 60(4):739-44. PubMed ID: 11968781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.
    Bannister WP; Cozzi-Lepri A; Kjær J; Clotet B; Lazzarin A; Viard JP; Kronborg G; Duiculescu D; Beniowski M; Machala L; Phillips A;
    J Antimicrob Chemother; 2011 Apr; 66(4):901-11. PubMed ID: 21393179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies.
    Boffito M; Pillay D; Wilkins E
    Int J Clin Pract; 2006 Sep; 60(9):1098-106. PubMed ID: 16939552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and challenges of antiretroviral research and therapy.
    Esté JA; Cihlar T
    Antiviral Res; 2010 Jan; 85(1):25-33. PubMed ID: 20018390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple-class HIV antiretroviral therapy failure in an Australian primary care setting.
    Bloch M; Farris M; Tilden D; Gowers A; Cunningham N
    Sex Health; 2010 Mar; 7(1):17-24. PubMed ID: 20152091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.